Please assess the completion status of the following clinical trial:

Trial Title: Vasculopathic Injury and Plasma as Endothelial Rescue - OCTAplas Trial (EudraCT no. 2014-000452-28)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient eligible for emergency surgery on cardiopulmonary bypass pump for a thoracic aortic dissections AND~* Age \> 18 years AND~* Consent obtainable from patient or by proxy (independent physicians and/or next of kin)~Exclusion Criteria:~* Documented refusal of blood transfusion OR~* FFP transfusion before randomization OR~* Aortic dissection due to trauma OR~* Treatment with GPIIb/IIIa inhibitors \< 24h from screening OR~* Withdrawal from active therapy OR~* Expected to die \< 24h OR~* Previously within 30 days included in a randomized trial, if known at the time of enrolment~* Known IgA deficiency with documented antibodies against IgA~* Known hypersensitivity to OctaplasLG®: the active substance, any of the excipients (Sodium citrate dihydrate, Sodium dihydrogenphosphate dihydrate or Glycine) or residues from the manufacturing process (Tri (N-Butyl) Phosphate (TNBP) and Octoxynol (Triton X-100))~* Known severe deficiencies of protein S~* Pregnancy (non-pregnancy confirmed by patient being postmenopausal or having a negative serum-hCG)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- OctaplasLG® (Type: ACTIVE_COMPARATOR): replacement to bleeding
- Standard fresh frozen plasma (Type: PLACEBO_COMPARATOR): replacement to bleeding

Based on this trial design, predict the completion outcome and termination type (if applicable).